Report Overview:
Isovaleric acidemia (IVA) is a rare metabolic disorder characterized by the body's inability to properly break down the amino acid leucine, leading to the accumulation of isovaleric acid. Left untreated, IVA can result in severe health problems and even death. Treatment for IVA primarily involves dietary management, including a low-protein diet and the use of specialized medical formulas. The market for IVA treatment primarily consists of specialized medical foods, dietary supplements, and medications designed to help manage the condition.
This report provides a deep insight into the global Isovaleric Acidemia Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Isovaleric Acidemia Treatment market size was estimated at USD 598 million in 2024 and is projected to reach USD 976.51 million by 2032, exhibiting a CAGR of 5.60% during the forecast period.
By Types:
• L-Carnitine Supplements
• Glycine Supplements
By Applications: Hospital
Key players include:
• Amgen
• Replimune Group Inc.
• Transgene SA
• Oncolys BioPharma
• Targovax
• Lokon Pharma
• Vyriad
• Including or Excluding key companies relevant to your analysis.
